The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Medivation Announces Participation in the UBS Global Life Sciences Conference

Tuesday, September 14, 2010

Medivation Announces Participation in the UBS Global Life Sciences Conference08:00 EDT Tuesday, September 14, 2010SAN FRANCISCO, Sept. 14 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the UBS Global Life Sciences Conference on Tuesday, September 21, at 8:30 a.m. Eastern Time at the Grand Hyatt in New York. Dr. Hung will provide an overview of Medivation and its clinical development programs for dimebon (latrepirdine) for Alzheimer's and Huntington diseases and MDV3100 for prostate cancer. Live audio webcasts of the presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at www.medivation.com. A replay also will be available for 30 days following the live presentation. About Medivation Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a clinical development program that includes CONCERT, a Phase 3 trial assessing dimebon in patients with mild-to-moderate Alzheimer's disease, and HORIZON, a Phase 3 trial of dimebon in Huntington disease. In October 2009, Medivation entered into a global agreement with Astellas Pharma Inc. to develop and commercialize MDV3100 for both early- and late-stage prostate cancer. The first Phase 3 clinical trial in the MDV3100 development program, known as the AFFIRM trial, is under way in patients with advanced metastatic prostate cancer who have previously been treated with docetaxel-based chemotherapy. Additional trials in earlier-stage prostate cancer will begin in 2010. For more information, please visit us at www.medivation.com.  SOURCE Medivation, Inc.For further information: Patrick Machado, Chief Financial Officer of Medivation, Inc., +1-415-829-4101; or Nicole Foderaro of WCG, +1-415-946-1058, for Medivation, Inc.